Company news

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) news

Recursion Pharmaceuticals, Inc. news releases on 6ix. Latest, Aug 5, 2026: Recursion Reports Second Quarter Financial Results; Genentech Options First…

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) news

Press releases & updates

Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program

Recursion to Report Second Quarter 2026 Business Updates and Financial Results on August 5th

Remix Therapeutics to Present at AACR Drug Discovery and Development Conference

Recursion Reports First Quarter Financial Results and Provides Business Update

Recursion Announces Board Transition

Recursion to Report First Quarter 2026 Business Updates and Financial Results on May 6

Recursion Expands Strategic Partnership with Citeline to Advance Its AI-Enabled ClinTech Platform

Recursion Announces Vicki Goodman, M.D., as Incoming Chief Medical Officer

PacBio Announces the Appointment of Chris Gibson to the Board of Directors

Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Recursion To Be Featured in HighRes’ Lightning Talk at NVIDIA GTC

Recursion to Report Fourth Quarter and Full Year 2025 Business Updates and Financial Results on February 25

Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference

Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks

Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025

Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update

Recursion Announces CEO Transition Plan to Drive Next Phase of Growth

Recursion to Participate in Upcoming Investor Conferences

Recursion to Report Third Quarter 2025 Business Updates and Financial Results on November 5th

Rallybio Reports Second Quarter 2025 Financial Results and Provides Business Updates

Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update

Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th

Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals

Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia

MIT and Recursion Release Boltz-2: Next Generation AI Model to Predict Binding Affinity at Unprecedented Speed, Scale, and Accuracy

Recursion Reports First Quarter 2025 Financial Results and Provides Business Update

Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden

Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th

Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025

HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data

Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries

Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas

Recursion to Participate in Upcoming Investor Conference

Recursion Bolsters Board of Directors with Former FDA Principal Deputy Commissioner Dr. Namandjé Bumpus and Mammoth Biosciences COO and CFO Elaine Sun

Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Recursion to Report Fourth Quarter and Fiscal Year 2024 Business Updates and Financial Results on February 28th

Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference

Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More

Recursion to Present at 43rd Annual JP Morgan Healthcare Conference

Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability

Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma

Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery

Recursion and Exscientia Shareholders Approve the Proposed Combination

Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud’s Model Garden

Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results

Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection

Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma